Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

784 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Drug Survival of IL-12/23, IL-17 and IL-23 Inhibitors for Psoriasis Treatment: A Retrospective Multi-Country, Multicentric Cohort Study.
Torres T, Puig L, Vender R, Lynde C, Piaserico S, Carrascosa JM, Gisondi P, Daudén E, Conrad C, Mendes-Bastos P, Ferreira P, Leite L, Lu JD, Valerio J, Bruni M, Messina F, Nidegger A, Llamas-Velasco M, Del Alcazar E, Mufti A, White K, Caldarola G, Teixeira L, Romanelli P, Desai K, Gkalpakiotis S, Romanelli M, Yeung J, Nogueira M, Chiricozzi A. Torres T, et al. Among authors: puig l. Am J Clin Dermatol. 2021 Jul;22(4):567-579. doi: 10.1007/s40257-021-00598-4. Epub 2021 Mar 30. Am J Clin Dermatol. 2021. PMID: 33786754
[Clinical characteristics and disease course in patients treated with efalizumab following suspension of marketing authorization by the European medicines agency: a multicenter observational study].
Morell L, Carrascosa JM, Ferrándiz C, García-Bustinduy M, Fonseca E, Carretero G, Daudén E, Marrón SE, López-Estebaranz JL, Ferrán M, Sánchez-Regaña M, Muñoz-Santos C, Belinchón I, Puig L; Grupo Español de Psoriasis. Morell L, et al. Among authors: puig l. Actas Dermosifiliogr. 2011 Jun;102(5):354-64. doi: 10.1016/j.ad.2010.12.013. Epub 2011 Apr 29. Actas Dermosifiliogr. 2011. PMID: 21530928 Free article. Spanish.
Impact of ixekizumab on psoriasis itch severity and other psoriasis symptoms: Results from 3 phase III psoriasis clinical trials.
Kimball AB, Luger T, Gottlieb A, Puig L, Kaufmann R, Nikaï E, Zhu B, Edson-Heredia E, Carlier H, Lin CY, Goldblum O, Yosipovitch G. Kimball AB, et al. Among authors: puig l. J Am Acad Dermatol. 2016 Dec;75(6):1156-1161. doi: 10.1016/j.jaad.2016.07.034. Epub 2016 Sep 27. J Am Acad Dermatol. 2016. PMID: 27692498 Clinical Trial.
Efficacy and Safety of Switching to Ixekizumab in Etanercept Non-Responders: A Subanalysis from Two Phase III Randomized Clinical Trials in Moderate-to-Severe Plaque Psoriasis (UNCOVER-2 and -3).
Blauvelt A, Papp KA, Griffiths CEM, Puig L, Weisman J, Dutronc Y, Kerr LF, Ilo D, Mallbris L, Augustin M. Blauvelt A, et al. Among authors: puig l. Am J Clin Dermatol. 2017 Apr;18(2):273-280. doi: 10.1007/s40257-016-0246-9. Am J Clin Dermatol. 2017. PMID: 28074446 Free PMC article. Clinical Trial.
Correction to: Efficacy and Safety of Switching to Ixekizumab in Etanercept Non-Responders: A Subanalysis from Two Phase III Randomized Clinical Trials in Moderate-to-Severe Plaque Psoriasis (UNCOVER-2 and -3).
Blauvelt A, Papp KA, Griffiths CEM, Puig L, Weisman J, Dutronc Y, Kerr LF, Ilo D, Mallbris L, Augustin M. Blauvelt A, et al. Among authors: puig l. Am J Clin Dermatol. 2018 Jun;19(3):457. doi: 10.1007/s40257-018-0353-x. Am J Clin Dermatol. 2018. PMID: 29600394 Free PMC article.
784 results